APA (7th ed.) Citation

Váraljai, R., Zimmer, L., Al-Matary, Y., Kaptein, P., Albrecht, L. J., Shannan, B., . . . Roesch, A. (2023). Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nature cancer, 4(9), . https://doi.org/10.1038/s43018-023-00610-2

Chicago Style (17th ed.) Citation

Váraljai, Renáta, et al. "Interleukin 17 Signaling Supports Clinical Benefit of Dual CTLA-4 and PD-1 Checkpoint Inhibition in Melanoma." Nature Cancer 4, no. 9 (2023). https://doi.org/10.1038/s43018-023-00610-2.

MLA (9th ed.) Citation

Váraljai, Renáta, et al. "Interleukin 17 Signaling Supports Clinical Benefit of Dual CTLA-4 and PD-1 Checkpoint Inhibition in Melanoma." Nature Cancer, vol. 4, no. 9, 2023, https://doi.org/10.1038/s43018-023-00610-2.